719 related articles for article (PubMed ID: 26486925)
1. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
2. Management of vascular Behçet's disease.
Alibaz-Oner F; Direskeneli H
Int J Rheum Dis; 2019 Jan; 22 Suppl 1():105-108. PubMed ID: 29665281
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in Behçet's disease.
Shek LP; Lim DL
Biomed Pharmacother; 2002 Feb; 56(1):31-5. PubMed ID: 11908493
[TBL] [Abstract][Full Text] [Related]
5. Systemic vasculitis and the gut.
Hatemi I; Hatemi G; Çelik AF
Curr Opin Rheumatol; 2017 Jan; 29(1):33-38. PubMed ID: 27684357
[TBL] [Abstract][Full Text] [Related]
6. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
10. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide responsiveness in an infant with Behçet's syndrome.
Shek LP; Lee YS; Lee BW; Lehman TJ
Pediatrics; 1999 Jun; 103(6 Pt 1):1295-7. PubMed ID: 10353947
[TBL] [Abstract][Full Text] [Related]
12. Switching of anti-TNF-α agents in Behçet's disease.
Furuta S; Chow YW; Chaudhry AN; Jayne D
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S62-8. PubMed ID: 23010387
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center.
Hatemi I; Esatoglu SN; Hatemi G; Erzin Y; Yazici H; Celik AF
Medicine (Baltimore); 2016 Apr; 95(16):e3348. PubMed ID: 27100417
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
[No Abstract] [Full Text] [Related]
15. Sucessful use of thalidomide in severe gastrointestinal Behçet's disease.
Lim YK; Keating JP; Steele R
ANZ J Surg; 2015 Jun; 85(6):496. PubMed ID: 26031928
[No Abstract] [Full Text] [Related]
16. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
17. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.
Ozguler Y; Leccese P; Christensen R; Esatoglu SN; Bang D; Bodaghi B; Çelik AF; Fortune F; Gaudric J; Gul A; Kötter I; Mahr A; Moots RJ; Richter J; Saadoun D; Salvarani C; Scuderi F; Sfikakis PP; Siva A; Stanford M; Tugal-Tutkun I; West R; Yurdakul S; Olivieri I; Yazici H; Hatemi G
Rheumatology (Oxford); 2018 Dec; 57(12):2200-2212. PubMed ID: 30107448
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide: focus on its employment in rheumatologic diseases.
Ossandon A; Cassarà EA; Priori R; Valesini G
Clin Exp Rheumatol; 2002; 20(5):709-18. PubMed ID: 12412207
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
